Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis

医学 荟萃分析 精神分裂症(面向对象编程) 耐受性 精神科 内科学 不利影响
作者
Maximilian Huhn,Adriani Nikolakopoulou,Johannes Schneider‐Thoma,Marc Krause,Myrto T. Samara,Natalie Luise Peter,Thomas J. Arndt,Lio Bäckers,Philipp Rothe,Andrea Cipriani,John M. Davis,Georgia Salanti,Stefan Leucht
出处
期刊:The Lancet [Elsevier BV]
卷期号:394 (10202): 939-951 被引量:1982
标识
DOI:10.1016/s0140-6736(19)31135-3
摘要

BACKGROUND: Schizophrenia is one of the most common, burdensome, and costly psychiatric disorders in adults worldwide. Antipsychotic drugs are its treatment of choice, but there is controversy about which agent should be used. We aimed to compare and rank antipsychotics by quantifying information from randomised controlled trials. METHODS: We did a network meta-analysis of placebo-controlled and head-to-head randomised controlled trials and compared 32 antipsychotics. We searched Embase, MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane Central Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov from database inception to Jan 8, 2019. Two authors independently selected studies and extracted data. We included randomised controlled trials in adults with acute symptoms of schizophrenia or related disorders. We excluded studies in patients with treatment resistance, first episode, predominant negative or depressive symptoms, concomitant medical illnesses, and relapse-prevention studies. Our primary outcome was change in overall symptoms measured with standardised rating scales. We also extracted data for eight efficacy and eight safety outcomes. Differences in the findings of the studies were explored in metaregressions and sensitivity analyses. Effect size measures were standardised mean differences, mean differences, or risk ratios with 95% credible intervals (CrIs). Confidence in the evidence was assessed using CINeMA (Confidence in Network Meta-Analysis). The study protocol is registered with PROSPERO, number CRD42014014919. FINDINGS: We identified 54 417 citations and included 402 studies with data for 53 463 participants. Effect size estimates suggested all antipsychotics reduced overall symptoms more than placebo (although not statistically significant for six drugs), with standardised mean differences ranging from -0·89 (95% CrI -1·08 to -0·71) for clozapine to -0·03 (-0·59 to 0·52) for levomepromazine (40 815 participants). Standardised mean differences compared with placebo for reduction of positive symptoms (31 179 participants) varied from -0·69 (95% CrI -0·86 to -0·52) for amisulpride to -0·17 (-0·31 to -0·04) for brexpiprazole, for negative symptoms (32 015 participants) from -0·62 (-0·84 to -0·39; clozapine) to -0·10 (-0·45 to 0·25; flupentixol), for depressive symptoms (19 683 participants) from -0·90 (-1·36 to -0·44; sulpiride) to 0·04 (-0·39 to 0·47; flupentixol). Risk ratios compared with placebo for all-cause discontinuation (42 672 participants) ranged from 0·52 (0·12 to 0·95; clopenthixol) to 1·15 (0·36 to 1·47; pimozide), for sedation (30 770 participants) from 0·92 (0·17 to 2·03; pimozide) to 10·20 (4·72 to 29·41; zuclopenthixol), for use of antiparkinson medication (24 911 participants) from 0·46 (0·19 to 0·88; clozapine) to 6·14 (4·81 to 6·55; pimozide). Mean differences compared to placebo for weight gain (28 317 participants) ranged from -0·16 kg (-0·73 to 0·40; ziprasidone) to 3·21 kg (2·10 to 4·31; zotepine), for prolactin elevation (21 569 participants) from -77·05 ng/mL (-120·23 to -33·54; clozapine) to 48·51 ng/mL (43·52 to 53·51; paliperidone) and for QTc prolongation (15 467 participants) from -2·21 ms (-4·54 to 0·15; lurasidone) to 23·90 ms (20·56 to 27·33; sertindole). Conclusions for the primary outcome did not substantially change after adjusting for possible effect moderators or in sensitivity analyses (eg, when excluding placebo-controlled studies). The confidence in evidence was often low or very low. INTERPRETATION: There are some efficacy differences between antipsychotics, but most of them are gradual rather than discrete. Differences in side-effects are more marked. These findings will aid clinicians in balancing risks versus benefits of those drugs available in their countries. They should consider the importance of each outcome, the patients' medical problems, and preferences. FUNDING: German Ministry of Education and Research and National Institute for Health Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
做好人难完成签到,获得积分10
刚刚
1秒前
1秒前
Akim的应助被xin采纳,获得10
1秒前
Horace完成签到,获得积分10
1秒前
C1发布了新的文献求助10
1秒前
甜崽小肉丸完成签到,获得积分10
1秒前
zhiyuanli发布了新的文献求助10
1秒前
iOhyeye23完成签到 ,获得积分10
1秒前
cora发布了新的文献求助20
1秒前
1秒前
酷炫的康发布了新的文献求助10
1秒前
汉堡包的应助被YX采纳,获得10
1秒前
2秒前
可乐不加冰完成签到,获得积分10
2秒前
2秒前
2秒前
tomato完成签到,获得积分10
2秒前
汉堡包的应助被muyan采纳,获得10
2秒前
陈文思完成签到 ,获得积分10
2秒前
PenStand完成签到,获得积分10
2秒前
妮妮发布了新的文献求助10
3秒前
孤独芷烟完成签到,获得积分10
4秒前
幻天游发布了新的文献求助10
4秒前
XAaaaa发布了新的文献求助10
4秒前
4秒前
DW的应助被夏侯初采纳,获得10
5秒前
5秒前
852的应助被pufanlg采纳,获得30
5秒前
科研通AI6.4的应助被warm采纳,获得10
5秒前
lixun完成签到 ,获得积分10
5秒前
5秒前
6秒前
6秒前
逆光发布了新的文献求助10
6秒前
酷炫的康完成签到,获得积分10
6秒前
6秒前
Tardes发布了新的文献求助10
6秒前
红梅发布了新的文献求助10
6秒前
狂野妙菱完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175853
求助须知:如何正确求助?哪些是违规求助? 9567457
关于积分的说明 21792632
捐赠科研通 7770447
什么是DOI,文献DOI怎么找? 3431918
关于科研通互助平台的介绍 2556276
邀请新用户注册赠送积分活动 2477418